Specialty Pharma Journal Specialty, Precision & Technology
LAUSANNE, Switzerland–(BUSINESS WIRE)–Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early …
Read More »Novigenix and RadioMedix to Develop Neuroendocrine Cancer Precision Diagnostic Test
Recent Posts
FDA Approves Lilly’s Reyvow, the First and Only Medicine in a New Class of Acute Treatment for Migraine
INDIANAPOLIS, Oct. 11, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug …
Read More »Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in Late-Stage Rheumatoid Arthritis Studies
FOSTER CITY, Calif. & MECHELEN, Belgium–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext …
Read More »New Head-to-Head Data Show Taltz Superiority vs. Tremfya in Patients with Moderate to Severe Plaque Psoriasis
TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) — Eli Lilly and Company presented detailed data at …
Read More »RedHill Biopharma Announces Full Results from Phase 3 Study and Supportive Top-Line Results from Open-Label Extension Study with RHB-104 in Crohn’s Disease
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 11, 2019 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock …
Read More »New Technologies Offer the Possibility of Identifying Cancer from a Single Blood Draw
ALEXANDRIA, Va. – Two blood tests show promise as screening tools to identify patients with cancer …
Read More »Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases
BOSTON–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Stealth BioTherapeutics Corp (NASDAQ:MITO) today announced an agreement for an option to …
Read More »Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research
PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development …
Read More »FDA Grants Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
RIDGEFIELD, Conn., Oct. 10, 2019 /PRNewswire/ — Boehringer Ingelheim announced today that the U.S. Food and Drug …
Read More »UCB to Acquire Ra Pharmaceuticals for $2.5 Billion, Expanding its Rare Disease Drug Pipeline
BRUSSELS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–regulated information – inside information – UCB and Ra Pharmaceuticals Inc. (NASDAQ: …
Read More »Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis
LAUSANNE, Switzerland–(BUSINESS WIRE)–Galderma, a global leader focused on meeting the world’s increasing skin health needs, …
Read More »Reata Reacquires Rights from AbbVie to Develop and Commercialize Bardoxolone Methyl, Omaveloxolone, and All Next-Generation Nrf2 Activators
IRVING, Texas, Oct. 10, 2019 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage …
Read More »ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 10, 2019 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), …
Read More »bluebird bio and Novo Nordisk Partner to Develop in vivo Genome Editing Candidates for Hemophilia and Other Severe Genetic Diseases
CAMBRIDGE, Mass. and BAGSVÆRD, Denmark–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO) today …
Read More »GE Healthcare and Theragnostics Enter Global Commercial Partnership for Late Stage PSMA Diagnostic for Prostate Cancer
LONDON, Oct. 9, 2019 /PRNewswire/ — GE Healthcare and Theragnostics have entered into a global …
Read More »